Skip to main content
. 2013 Sep 23;2013:604301. doi: 10.1155/2013/604301

Figure 1.

Figure 1

Patient 3. Forehead basal cell carcinoma lesions before everolimus treatment (a) and after six months of everolimus 3 mg daily (b).

HHS Vulnerability Disclosure